IP Library Granted Patent US 9,999,702
Granted Patent B2
US 9,999,702 · App. 14/135,088 · Granted Jun 19, 2018

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

Inventors: Dmitry Zimnitsky (Pennington, NJ); Jenny Finkbiner (Fremont, CA); Blane Sanders (San Antonio, TX)
Assignee: KCI Licensing Inc.
A61L26/0038A61F13/00068A61K31/085A61K31/14A61K31/155A61K31/381A61K31/785A61K33/26A61L26/0066A61M1/0088A61F2013/0017A61F2013/00174A61L2300/404A61L2300/414A61L2300/434A61M1/0084
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,999,702
App. No.
14/135,088
Granted
Jun 19, 2018
Kind
B2
Abstract

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.

Claims (18)

1. A method for promoting wound healing by reducing excessive matrix metalloprotease activity, comprising contacting a wound site with a composition to preserve granulation tissue, the composition for reducing excessive matrix metalloprotease activity, wherein the composition comprises gelatin as a sacrificial matrix metalloprotease substrate having exposed peptide sequences that serve as signals for matrix metalloprotease binding, and wherein the composition further comprises ethylenediaminetetraacetic acid as a component for reducing matrix metalloprotease activity, the composition being coated on at least a portion of a wound dressing comprising open-cell foam having a plurality of passages formed from pores within the open-cell foam to distribute a reduced pressure to the wound site, wherein the open-cell foam has exterior surfaces and interior surfaces defined by the plurality of passages, and wherein the composition comprising gelatin and ethylenediaminetetraacetic acid is coated on at least a portion of an exterior surface of the open-cell foam and along at least a portion of the plurality of passages.

2. The method of claim 1 , wherein the composition comprises 0.1% to 25% w/w gelatin.

3. The method of claim 1 , wherein the composition further comprises an antimicrobial agent, a growth factor, a proteinase inhibitor, or a preservative.

4. The method of claim 3 , wherein the antimicrobial agent is non-ionic silver, polyhexamethylene biguanide, chlorhexidine, benzalconium chloride or triclosan.

5. The method of claim 1 , further comprising:

positioning the wound dressing adjacent the wound site;

positioning a drape over the wound dressing to create a sealable space;

delivering the reduced pressure to the sealable space;

promoting new tissue growth at the wound site by exposing the wound site to the reduced pressure; and

increasing an area of contact between the wound site and the wound dressing to increase the exposure of the wound site to the composition comprising gelatin.

6. The method of claim 5 , wherein increasing an area of contact further comprises:

microdeforming tissue at the wound site under the influence of the reduced pressure.

7. The method of claim 5 , wherein increasing an area of contact further comprises:

compressing the wound dressing under the influence of the reduced pressure.

8. The method of claim 5 further comprising:

reducing inflammation at the wound site by increasing exposure of tissue at the wound site to the composition comprising gelatin.

9. The method of claim 5 further comprising:

reducing inflammation at the wound by removing body-liquid from the wound site into the passages and by exposing the body-liquid in the passages to the composition comprising gelatin.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066445/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2023
From: KCI LICENSING, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 064730/0218 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2015
From: ZIMNITSKY, DMITRY; FINKBINER, JENNY; SANDERS, BLANE
To: KCI LICENSING, INC.
Reel/Frame 036076/0963 →
Continuity (2)
Division 12757562 · Apr 9, 2010
Related Publication 20150174291A1 · Jun 25, 2015